Barclays Lowers Certara (NASDAQ:CERT) Price Target to $14.00

Certara (NASDAQ:CERT - Get Free Report) had its target price reduced by equities researchers at Barclays from $16.00 to $14.00 in a research note issued on Tuesday, Benzinga reports. The firm currently has an "equal weight" rating on the stock. Barclays's price objective would indicate a potential upside of 24.89% from the stock's previous close.

Several other research firms have also commented on CERT. KeyCorp reduced their price objective on shares of Certara from $23.00 to $20.00 and set an "overweight" rating for the company in a research note on Thursday, July 11th. JMP Securities restated a "market perform" rating on shares of Certara in a research note on Wednesday, July 10th. UBS Group upgraded shares of Certara from a "neutral" rating to a "buy" rating and set a $16.00 price target on the stock in a research note on Friday, September 27th. Finally, Robert W. Baird cut their price target on shares of Certara from $19.00 to $18.00 and set a "neutral" rating on the stock in a research note on Wednesday, August 7th. Six research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, Certara has a consensus rating of "Hold" and a consensus target price of $17.08.

Certara Stock Down 0.3 %

Shares of CERT traded down $0.03 during mid-day trading on Tuesday, hitting $11.21. The company's stock had a trading volume of 950,945 shares, compared to its average volume of 747,440. The company has a current ratio of 2.61, a quick ratio of 2.61 and a debt-to-equity ratio of 0.28. The firm has a market capitalization of $1.80 billion, a price-to-earnings ratio of -28.74, a PEG ratio of 5.40 and a beta of 1.49. The company's 50-day moving average is $11.71 and its 200-day moving average is $14.50. Certara has a 52-week low of $10.35 and a 52-week high of $19.87.

Certara (NASDAQ:CERT - Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). The firm had revenue of $93.31 million for the quarter, compared to the consensus estimate of $96.01 million. Certara had a positive return on equity of 3.03% and a negative net margin of 21.64%. The company's revenue was up 3.2% compared to the same quarter last year. During the same quarter last year, the firm earned $0.10 EPS. On average, equities research analysts forecast that Certara will post 0.27 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Leif E. Pedersen sold 51,224 shares of the stock in a transaction on Monday, September 9th. The shares were sold at an average price of $11.29, for a total transaction of $578,318.96. Following the sale, the insider now directly owns 99,704 shares of the company's stock, valued at approximately $1,125,658.16. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, insider Patrick F. Smith sold 5,409 shares of the firm's stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $11.03, for a total value of $59,661.27. Following the transaction, the insider now directly owns 50,091 shares of the company's stock, valued at approximately $552,503.73. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Leif E. Pedersen sold 51,224 shares of the firm's stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $11.29, for a total transaction of $578,318.96. Following the completion of the transaction, the insider now directly owns 99,704 shares in the company, valued at approximately $1,125,658.16. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.39% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Certara

Hedge funds and other institutional investors have recently bought and sold shares of the company. Blue Trust Inc. acquired a new stake in Certara during the second quarter worth about $26,000. Innealta Capital LLC acquired a new stake in shares of Certara during the second quarter valued at about $36,000. Intech Investment Management LLC acquired a new stake in shares of Certara during the second quarter valued at about $152,000. Algert Global LLC acquired a new stake in shares of Certara during the second quarter valued at about $156,000. Finally, MQS Management LLC acquired a new stake in shares of Certara during the second quarter valued at about $162,000. 73.96% of the stock is currently owned by institutional investors and hedge funds.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.